Objective. To assess the influence of disease activity on platelet function in patients with inflammatory arthritis (IA).
Introduction
Following a diagnosis of inflammatory arthritis (IA) (RA, PsA, AS and seronegative SpA), the 10-year risk of myocardial infarction is more than twice that of the general population and is equivalent to that of patients with Type 2 diabetes mellitus [1] . While traditional risk factors are known to play a role in the pathogenesis of cardiovascular events, recent work has highlighted the key role of inflammation in atherothrombosis [2] and as a risk factor for cardiovascular disease (CVD) in patients with RA [3] . Myocardial infarction results from a complex chain of events leading to the thrombotic occlusion of a coronary artery. Platelets are central to the development of these thrombotic events [2] . It is well established that inflammation activates platelets [4] and that platelet-derived mediators in turn potentiate the inflammatory response [2] . To date, platelet function in the IA population has not been well characterized. Previous studies have shown that patients with inflammatory rheumatic conditions exhibit increased in vitro platelet aggregation [5] . However, these patients were not characterized in terms of disease activity. More recent studies have shown a strong correlation between elevated markers of disease activity (CRP, ESR) and markers of platelet activation (CD62P, CD63) in RA [6] . However, the functional responsiveness or reactivity of these platelets was not assessed.
Platelet reactivity is a measure of how easily platelets will adhere to one another to form thrombus. Several lines of evidence suggest that platelet reactivity is useful in clinical practice to predict the risk of future adverse cardiovascular events [7, 8] .
Therefore, we decided to examine platelet reactivity in the IA population and assess the influence of disease activity on platelet function. Standard platelet function assays using light transmission aggregometry typically assess the platelet response to single agonists at maximal concentrations and have limited clinical applicability [9] . Platelet aggregation in vivo is complex and involves multiple agonists, receptorÀeffector mechanisms and signalling pathways [2] . We developed an assay that measures the response of platelets to multiple agonists at multiple concentrations, simultaneously [10] . We used this novel assay of platelet reactivity and compared the ex vivo platelet function of patients with active inflammatory disease to that of patients with no clinical evidence of inflammation.
Patients and methods
Ethical approval was obtained from the Mater Misericordiae Hospital Ethics Committee and the study complied with the Declaration of Helsinki. Informed consent was obtained from all patients prior to phlebotomy.
Patients
Patients attending the rheumatology outpatient clinic were recruited. Only patients with an established diagnosis of IA (RA, PsA, AS, seronegative SpA, gout and Still's disease) and those aged between 18 and 70 years were considered for inclusion. Patients with a prior history of ischaemic heart disease, diabetes mellitus and those receiving anti-platelet therapy (aspirin, clopidogrel, ticlopidine or dipyrimadole) or thromboembolic prophylaxis (heparin or warfarin) were excluded.
Patients with a serum creatinine >140 mmol/l, a platelet count <120 000/mm 3 , or who were pregnant or had hepatic dysfunction (defined by hepatic enzymes more than twice the upper limit of normal) were also excluded.
Disease activity
Several methods were used to accurately determine the disease activity. An initial assessment based on history and clinical examination was performed on all patients by the same clinician. All patients were then examined by a clinical nurse specialist. 
Phlebotomy and platelet preparation
For detailed methodology regarding blood sampling and platelet preparation see supplementary data available at Rheumatology online.
Platelet function assay
To assess the platelet function, we used a novel platelet function assay based on a modification of light transmission aggregometry, described in detail elsewhere [10] (see supplementary data available at Rheumatology Online).
Patient groups
The entire cohort was divided into two separate groups based on disease activity. Those with clinically active disease were assigned to the active group, whereas those patients with well-controlled disease were assigned to the control group. This assignment was made independent of platelet function. Platelet assay data were recorded and both the platelet assay data and clinical data were merged thereafter.
Statistical analysis
Demographic data categorical variables were analysed using the Fisher's Exact Test. Disease activity data were analysed using the Wilcoxon signed-rank test. Platelet function data continuous variables were tested for normality using the D'Agostino-Pearson omnibus test. Analysis of variance (ANOVA) for per cent platelet aggregation was then assessed by repeated measures two-way ANOVA. The nominal level of significance was 5% and multiple comparisons between different agonist concentrations were adjusted using the Bonferroni correction. Sigmoidal dose-response curves for the two groups were compared separately for each agonist using the extra sum-ofsquares F-test.
Results
One hundred and seven patients were initially enrolled in the study. Eleven patients were excluded for the following reasons: four from whom a sufficient blood sample for platelet analysis could not be obtained; five for failure to complete the assay within the timeframe and two where complete baseline serological data were missing.
Data from a total of 96 patients were analysed. The average time from drawing the blood to completion of the assay was 40 ± 5 min.
Patient characteristics
The two groups (active vs control) were similar in terms of age, gender, diagnosis and traditional cardiovascular risk factors (Table 1) . The majority of patients (65%) were diagnosed with RA. There were significant differences between the two groups in their use of medications. Anti-TNF-a therapy use was significantly higher in the control group (P = 0.0062), whereas NSAID use was significantly higher in the active disease group (P = 0.0017).
Disease activity data for the active vs control disease groups are also shown in Table 1 . There are significant differences in all of these variables between the two groups. DAS-28 scores for those patients with RA are shown separately.
Coagulation profiles, prothrombin and partial thromboplastin times were similar in both groups, and all were within the normal range.
Mean platelet count was higher in the active group (95% CI 303, 391 Â 10 9 /l) than the control group (95% CI 266, 315 Â 10 9 /l). However, both fall within the normal range (150, 450 Â 10 9 /l).
Platelet function data
Sigmoidal dose-response curves of per cent platelet aggregation in response to increasing concentrations of agonist for the active and control disease groups were directly compared with each other. There is a sigificant difference between the two groups in response to adenosine diphosphate (ADP) only (P < 0.001). The active disease group exhibits increased platelet reactivity at submaximal concentrations (Fig. 1) .
The dose-response curves for arachidonic acid, epinephrine, collagen and thrombin receptor activating peptide (TRAP) are similar for both groups (see supplementary figure 1 available as supplementary data at Rheumatology Online).
Per cent platelet aggregation values were normally distributed for all concentrations of agonists. ANOVA results for each agonist demonstrated a significant difference between the groups in response to ADP only (P = 0.01). The values obtained for the other agonists were: P = 0.25 for TRAP, P = 0.42 for collagen, P = 0.54 for arachidonic acid and P = 0.88 for epinephrine. The individual concentrations of ADP responsible for the significantly increased response in the active disease group are in the submaximal range (1.25, 2.5 and 5 mm), as demonstrated by the Bonferroni post-test values (P < 0.001).
We then exclusively examined those patients with a diagnosis of RA. A unique enhanced response to ADP was also seen at the same submaximal concentrations in those patients with active disease only (data not shown).
Discussion
The results of this investigation demonstrate a number of key findings. First, the patients in this study, with objective evidence of active IA, demonstrate increased platelet reactivity specifically to ADP. Secondly, there was no significant difference in platelet response to any of the other agonists in terms of disease activity. Thirdly, when maximal concentrations of agonists are used in platelet aggregation, there is no difference seen between the two groups. Epidemiological evidence has clearly shown that IA is an independent risk factor for CVD [1] and that this risk is greatest in those with chronic active disease [3] . Several lines of evidence support the use of platelet reactivity in predicting the risk of future cardiovascular events [7, 8] . Thus, the unique platelet hyper-reactivity in response to ADP in patients with active IA may explain some of this risk, and has implications for therapy.
Platelets express at least two ADP receptors: P2Y1 and P2Y12. Both are G-protein-coupled surface receptors. P2Y1 is a weak agonist of platelet aggregation, whereas the P2Y12 receptor is the major receptor involved in amplifying and sustaining platelet aggregation in response to ADP [2] . The therapeutic importance of the ADP-P2Y12 receptor interaction is evident from the reduction in adverse cardiovascular events when this receptor is inhibited with drugs such as ticlopidine and clopidogrel [12] .
The mechanisms underlying the enhanced platelet response to ADP in active IA are currently unexplained. Although mean platelet count was higher in the active group, it was within the normal range, and previous work has demonstrated that this does not account for differences in platelet aggregation measurements [13] . Increased receptor expression could account for this difference. However, whereas the platelet ADP-P2Y12 receptor has been cloned for some time, monoclonal antibodies to this receptor that are suitable for surface receptor quantification by flow cytometry are currently not commercially available.
Studies have shown an increased platelet responsiveness to ADP in insulin-resistant states [14] . Furthermore, insulin-resistant patients with elevated Fib levels treated with the ADP-P2Y12 antagonist clopidogrel, exhibit less inhibition of platelet reactivity in response to ADP than those with normal plasma Fib [15] . Interestingly, in our study, plasma Fib was the most consistently elevated serological marker of active disease. Several studies have demonstrated increased insulin resistance in patients with IA, and this is associated with active inflammation [16] . Insulin resistance has been shown to ameliorate in response to treatment with DMARDs, in particular anti-TNF-a agents [17] . The use of anti-TNF-a therapy was significantly higher in our controlled disease cohort and this group did not show the same response to ADP as compared with those with active IA. Moreover, insulin resistance is associated with abnormal platelet function [18] . Thus, a link among active inflammatory disease, insulin resistance, Fib and platelet ADP hyperresponsiveness seems possible. We did not evaluate insulin resistance prospectively in our patient study.
Platelet activation is associated with systemic inflammation and platelet-derived mediators of inflammation potentiate the inflammatory response [2] . The proinflammatory cytokine CD40 ligand is one such mediator, which is stored intracellularly and rapidly presents on the platelet surface after platelet activation [19] . This ligand is a trimeric transmembrane protein in the TNF family and when cleaved to its active soluble fragment it inhibits endothelial ecto-ADPase and induces the endothelium Fig. 1 Log dose-response curves for active vs control groups in response to ADP. Log of agonist concentration is plotted on the x-axis, whereas platelet per cent aggregation is plotted on the y-axis. Platelet aggregation is enhanced in the active group in response to submaximal concentrations of ADP. ***P < 0.001.
www.rheumatology.oxfordjournals.org to generate further pro-inflammatory mediators [19] . Interestingly, clopidogrel significantly inhibits ADP-induced CD40 ligand expression [19] . Furthermore, TNF-a has been shown to directly up-regulate CD40 ligand on the platelet surface in patients with heart failure [20] . Patients with active IA have markedly elevated TNF-a levels. It is possible that actively inflamed IA patients also up-regulate CD40 ligand expression and consequently have a physiological bias towards increased ADP bioavailability. We have already referred to the association between increased plasma Fib and platelet ADP hypersensitivity in the insulin-resistant state [15] and the fact that Fib levels were consistently elevated in our active disease cohort. Activated platelets bind Fib following a conformational change in the GPIIbIIIa receptor [2] . Intracellular platelet Fib stores are continuously replenished from the platelet external environment. Thus, patients with IA who have chronic active inflammation and insulin resistance may exhibit enhanced Fib binding in the setting of a hyper-reactive platelet ADP receptoreffector system.
In conclusion, it is well known that patients with IA have a markedly elevated risk of adverse cardiovascular events, and that this risk is greatest in those with poor disease control. The results of the present investigation demonstrate a unique enhanced response of platelets to ADP in patients with active disease. It is not known if specific anti-platelet therapy targeting the ADP receptor in patients with IA can reduce the cardiovascular risk in this patient cohort, and further studies in this area are warranted.
Rheumatology key messages
. Patients with active IA demonstrate enhanced platelet function, specific to the ADP pathway. . The increased platelet response to ADP may represent a pro-thrombotic bias in patients with inflammation. . Trials of targeted anti-platelet therapy should be considered in this population.
